サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Non-Alcoholic Steatohepatitis Biomarkers Market Research Report - Global Forecast till 2024

非アルコール性脂肪性肝炎(NASH)バイオマーカー市場調査レポート‐2024年までの世界予測

レポート概要

世界の非アルコール性脂肪性肝炎(NASH)バイオマーカー市場レポート:疾患の見通し別情報、種類別(血清バイオマーカー、肝線維症バイオマーカー、その他)、エンドユーザー(製薬企業&CRO、その他)、地域別‐2024年までの予測

市場概要

世界のNASHバイオマーカー市場は2024年までに20.92%のCAGRで拡大すると予想され、19億6,040万ドルに達する見込みです。NASHは非アルコール性脂肪性肝疾患(NAFLD)の一種で、その特徴は、肝臓に脂肪が蓄積することによって肝臓に炎症や損傷が発生します。現状ではNASHの診断に承認されている単一の検査法はありません。NASHの有病率の増加、非侵襲的診断検査の需要の増大、この疾患に対する認識を高めるための取組みの強化がこの市場の主な成長要因です。一方で、バイオマーカーの条件に関するFDAの厳しい規制の存在がこの市場の成長を妨げる要因となります。

市場動態

NASHの発症率は驚くべき速度で増え続けているため、効果的な診断ツールのニーズが高まっています。NASH Education Programが発表したデータによると、NASHの有病率は2015−2030年の間に63%増加すると予想されます。糖尿病や肥満症の有病率の上昇、非侵襲的検査の需要増大、NASHに関する認識を高めるための官民セクターの取組みが強化されていること、などが世界市場の成長を促す要因です。これらの推進要因の反面、不利な規制シナリオが市場にマイナスの影響を及ぼす可能性があります。

レポート詳細

章ごとの価格

このレポートは章ごとの個別販売も行っております。
以下の章ごとの価格は予期せず変更となる可能性がありますので、お問い合わせ下さい。
$ 0の記載がある章をご希望の方も、お問い合わせ下さい。
※全てPDFでの販売となります。

Title Price
1 Executive Summary $ 1,350
2 Market Introduction $ 0
3 Research Methodology $ 0
4 Market Dynamics $ 950
5 Market Factor Analysis $ 950
6 Global Non-Alcoholic Steatohepatitis Biomarkers Market, by Type $ 1,650
7 Global Non-Alcoholic Steatohepatitis Biomarkers Market, by End User $ 1,650
8 Global Non-Alcoholic Steatohepatitis Biomarkers Market, by Region $ 1,650
9 Competitive Landscape $ 1,050
10 Company Profiles $ 950
11 Appendix $ 0

目次

TABLE OF CONTENTS

1 Executive Summary
1.1 Market Attractiveness Analysis 16

2 Market Introduction
2.1 Definition 18
2.2 Scope of the Study 18
2.3 Assumptions 18
2.4 Market Structure 18

3 Research Methodology
3.1 Research Process 19
3.2 Primary Research 20
3.3 Secondary Research 21
3.4 Market Size Estimation 22
3.5 Forecast Model 22

4 Market Dynamics
4.1 Overview 23
4.2 Drivers 24
4.2.1 Increasing Prevalence of Diabetes and Obesity 24
4.2.2 Growing Demand for Non-invasive Tests 24
4.2.3 Rising Public and Private Sector Initiatives to Increase Awareness About NASH 24
4.3 Restraints 25
4.3.1 Stringent Regulatory Scenario 25
4.4 Opportunities 25
4.4.1 Growing Mergers and Acquisitions to Develop Novel Biomarkers 25

5 Market Factor Analysis
5.1 Value Chain Analysis 26
5.1.1 R&D and Designing 26
5.1.2 Manufacturing 26
5.1.3 Distribution & Sales 26
5.1.4 Post-Sales Review 27
5.2 Porter’s Five Forces Model 27
5.2.1 Bargaining Power of Suppliers 27
5.2.2 Bargaining Power of Buyers 28
5.2.3 Threat of New Entrants 28
5.2.4 Threat of Substitutes 28
5.2.5 Intensity of Rivalry 28
5.3 Pipeline Analysis 28
5.3.1 Overview 28
5.3.2 Recent Developments in Product Pipeline 29
5.4 Regulatory Landscape 29
5.5 Non-Alcoholic Steatohepatitis Biomarkers: Disease Cause Outlook 30
5.5.1 Overview 30
5.5.2 Obesity 30
5.5.3 Type 2 Diabetes 30
5.5.4 Hyperlipidemia 31
5.5.5 Hypertension 31
5.5.6 Metabolic Syndrome (MetS) 31

6 Global Non-Alcoholic Steatohepatitis Biomarkers Market, by Type
6.1 Overview 32
6.2 Serum Biomarkers 34
6.3 Hepatic Fibrosis Biomarkers 35
6.4 Apoptosis Biomarkers 37
6.5 Oxidative Stress Biomarkers 38
6.6 Others 38

7 Global Non-Alcoholic Steatohepatitis Biomarkers Market, by End User
7.1 Overview 39
7.2 Pharmaceutical Companies and CROs 41
7.3 Research Institutes and Academic Centers 42
7.4 Diagnostic Centers 43
7.5 Hospitals & Clinics 44

8 Global Non-Alcoholic Steatohepatitis Biomarkers Market, by Region
8.1 Overview 45
8.2 Americas 47
8.2.1 North America 49
8.2.2 Latin America 53
8.3 Europe 55
8.3.1 Western Europe 58
8.3.2 Eastern Europe 66
8.4 Asia-Pacific 67
8.4.1 Japan 69
8.4.2 China 70
8.4.3 India 71
8.4.4 Australia 72
8.4.5 South Korea 73
8.4.6 Rest of Asia-Pacific 74
8.5 Middle East & Africa 76
8.5.1 Middle East 78
8.5.2 Africa 79

9 Competitive Landscape
9.1 Overview 81
9.2 Key Development Analysis 82

10 Company Profiles
10.1 BioPredictive 83
10.1.1 Company Overview 83
10.1.2 Financial Overview 83
10.1.3 Products/Services Offered 83
10.1.4 Key Developments 83
10.1.5 SWOT Analysis 83
10.1.6 Key Strategies 84
10.2 Celerion 85
10.2.1 Company Overview 85
10.2.2 Financial Overview 85
10.2.3 Products/Services Offered 85
10.2.4 Key Developments 85
10.2.5 SWOT Analysis 85
10.2.6 Key Strategies 85
10.3 Cisbio 86
10.3.1 Company Overview 86
10.3.2 Financial Overview 86
10.3.3 Products/Services Offered 87
10.3.4 Key Developments 87
10.3.5 SWOT Analysis 88
10.3.6 Key Strategies 88
10.4 Echosens 89
10.4.1 Company Overview 89
10.4.2 Financial Overview 89
10.4.3 Products/Services Offered 89
10.4.4 Key Developments 89
10.4.5 SWOT Analysis 90
10.4.6 Key Strategies 90
10.5 Enterome 91
10.5.1 Company Overview 91
10.5.2 Financial Overview 91
10.5.3 Products/Services Offered 91
10.5.4 Key Developments 91
10.5.5 SWOT Analysis 91
10.5.6 Key Strategies 91
10.6 GENFIT 92
10.6.1 Company Overview 92
10.6.2 Financial Overview 92
10.6.3 Products/Services Offered 92
10.6.4 Key Developments 92
10.6.5 SWOT Analysis 93
10.6.6 Key Strategies 93
10.7 Laboratory Corporation of America Holdings 94
10.7.1 Company Overview 94
10.7.2 Financial Overview 94
10.7.3 Products/Services Offered 95
10.7.4 Key Developments 95
10.7.5 SWOT Analysis 95
10.7.6 Key Strategies 95
10.8 NGM Biopharmaceuticals 96
10.8.1 Company Overview 96
10.8.2 Financial Overview 96
10.8.3 Products/Services Offered 96
10.8.4 Key Developments 96
10.8.5 SWOT Analysis 96
10.8.6 Key Strategies 96
10.9 One Way Liver, SL 97
10.9.1 Company Overview 97
10.9.2 Financial Overview 97
10.9.3 Products/Services Offered 97
10.9.4 Key Developments 97
10.9.5 SWOT Analysis 97
10.9.6 Key Strategies 97
10.10 Pacific Biomarkers 98
10.10.1 Company Overview 98
10.10.2 Financial Overview 98
10.10.3 Products/Services Offered 98
10.10.4 Key Developments 98
10.10.5 SWOT Analysis 99
10.10.6 Key Strategies 99
10.11 Prometheus Laboratories Inc. 100
10.11.1 Company Overview 100
10.11.2 Financial Overview 100
10.11.3 Products/Services Offered 101
10.11.4 Key Developments 101
10.11.5 SWOT Analysis 101
10.11.6 Key Strategies 101
10.12 Perspectrum Diagnostics Ltd 102
10.12.1 Company Overview 102
10.12.2 Financial Overview 102
10.12.3 Products/Services Offered 102
10.12.4 Key Developments 102
10.12.5 SWOT Analysis 102
10.12.6 Key Strategies 102
10.13 Quest Diagnostics 103
10.13.1 Company Overview 103
10.13.2 Financial Overview 103
10.13.3 Products/Services Offered 104
10.13.4 Key Developments 104
10.13.5 SWOT Analysis 104
10.13.6 Key Strategies 104
10.14 Regulus Therapeutics, Inc. 105
10.14.1 Company Overview 105
10.14.2 Financial Overview 105
10.14.3 Products/Services Offered 105
10.14.4 Key Developments 105
10.14.5 SWOT Analysis 106
10.14.6 Key Strategies 106
10.15 Siemens Healthineers 107
10.15.1 Company Overview 107
10.15.2 Financial Overview 107
10.15.3 Products/Services Offered 108
10.15.4 Key Developments 108
10.15.5 SWOT Analysis 108
10.15.6 Key Strategies 108
10.16 Shenzhen New Industries Biomedical Engineering Co., Ltd 109
10.16.1 Company Overview 109
10.16.2 Financial Overview 109
10.16.3 Products/Services Offered 109
10.16.4 Key Developments 109
10.16.5 SWOT Analysis 109
10.16.6 Key Strategies 109
10.17 Xeptagen SpA 110
10.17.1 Company Overview 110
10.17.2 Financial Overview 110
10.17.3 Products/Services Offered 110
10.17.4 Key Developments 110
10.17.5 SWOT Analysis 110
10.17.6 Key Strategies 110

11 Appendix
11.1 References 111
11.2 Related Reports 111

12 List of Tables
TABLE 1 NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET: PIPELINE ANALYSIS 28
TABLE 2 NAFLD ASSOCIATED DISEASE CONDITIONS 30
TABLE 3 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 33
TABLE 4 GLOBAL NASH BIOMARKERS MARKET FOR SERUM BIOMARKERS, BY REGION, 2016-2024 (USD MILLION) 34
TABLE 5 CLASSIFICATION OF LIVER FIBROSIS BIOMARKERS 35
TABLE 6 GLOBAL NASH BIOMARKERS MARKET FOR HEPATIC FIBROSIS BIOMARKERS, BY REGION, 2016-2024 (USD MILLION) 36
TABLE 7 GLOBAL NASH BIOMARKERS MARKET FOR APOPTOSIS BIOMARKERS, BY REGION, 2016-2024 (USD MILLION) 37
TABLE 8 GLOBAL NASH BIOMARKERS MARKET FOR OXIDATIVE STRESS BIOMARKERS, BY REGION, 2016-2024 (USD MILLION) 38
TABLE 9 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 40
TABLE 10 GLOBAL NASH BIOMARKERS MARKET FOR PHARMACEUTICAL COMPANIES AND CRO, BY REGION, 2016-2024 (USD MILLION) 41
TABLE 11 GLOBAL NASH BIOMARKERS MARKET FOR RESEARCH INSTITUTES AND ACADEMIC CENTERS, BY REGION,
2016-2024 (USD MILLION) 42
TABLE 12 GLOBAL NASH BIOMARKERS MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2016-2024 (USD MILLION) 43
TABLE 13 GLOBAL NASH BIOMARKERS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2016-2024 (USD MILLION) 44
TABLE 14 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2016-2024 (USD MILLION) 46
TABLE 15 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2016-2024 (USD MILLION) 48
TABLE 16 AMERICAS: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 48
TABLE 17 AMERICAS: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 49
TABLE 18 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2016-2024 (USD MILLION) 50
TABLE 19 NORTH AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 50
TABLE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 51
TABLE 21 US: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 51
TABLE 22 US: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 52
TABLE 23 CANADA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 52
TABLE 24 CANADA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 53
TABLE 25 LATIN AMERICA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 53
TABLE 26 LATIN AMERICA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 54
TABLE 27 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2016-2024 (USD MILLION) 56
TABLE 28 EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 56
TABLE 29 EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 57
TABLE 30 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2016-2024 (USD MILLION) 58
TABLE 31 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 59
TABLE 32 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 59
TABLE 33 UK: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 60
TABLE 34 UK: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 60
TABLE 35 GERMANY: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 61
TABLE 36 GERMANY: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 61
TABLE 37 FRANCE: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 62
TABLE 38 FRANCE: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 62
TABLE 39 ITALY: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 63
TABLE 40 ITALY: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 63
TABLE 41 SPAIN: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 64
TABLE 42 SPAIN: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 64
TABLE 43 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 65
TABLE 44 REST OF WESTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 65
TABLE 45 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 66
TABLE 46 EASTERN EUROPE: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 66
TABLE 47 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2016-2024 (USD MILLION) 68
TABLE 48 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 68
TABLE 49 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 69
TABLE 50 JAPAN: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 69
TABLE 51 JAPAN: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 70
TABLE 52 CHINA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 70
TABLE 53 CHINA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 71
TABLE 54 INDIA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 71
TABLE 55 INDIA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 72
TABLE 56 AUSTRALIA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 72
TABLE 57 AUSTRALIA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 73
TABLE 58 SOUTH KOREA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 73
TABLE 59 SOUTH KOREA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 74
TABLE 60 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 74
TABLE 61 REST OF ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 75
TABLE 62 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2016-2024 (USD MILLION) 77
TABLE 63 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 77
TABLE 64 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 78
TABLE 65 MIDDLE EAST: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 78
TABLE 66 MIDDLE EAST: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 79
TABLE 67 AFRICA: NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 79
TABLE 68 AFRICA: NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 80
TABLE 69 TOP MANUFACTURERS IN THE GLOBAL NASH BIOMARKERS MARKET 81

13 List of Figures
FIGURE 1 MARKET SYNOPSIS 15
FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL NASH BIOMARKERS MARKET 16
FIGURE 3 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2018 (%) 16
FIGURE 4 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2016-2024 (USD MILLION) 17
FIGURE 5 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2018 (%) 17
FIGURE 6 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2016-2024 (USD MILLION) 17
FIGURE 7 GLOBAL NASH BIOMARKERS MARKET: MARKET STRUCTURE 18
FIGURE 8 RESEARCH PROCESS OF MRFR 19
FIGURE 9 TOP-DOWN & BOTTOM-UP APPROACH 22
FIGURE 10 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 23
FIGURE 11 VALUE CHAIN: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 26
FIGURE 12 PORTER’S FIVE FORCES ANALYSIS: GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKERS MARKET 27
FIGURE 13 GLOBAL NASH BIOMARKERS MARKET SHARE, BY TYPE, 2018 (%) 32
FIGURE 14 GLOBAL NASH BIOMARKERS MARKET, BY TYPE, 2018 AND 2024 (USD MILLION) 33
FIGURE 15 GLOBAL NASH BIOMARKERS MARKET SHARE, BY END USER, 2018 (%) 39
FIGURE 16 GLOBAL NASH BIOMARKERS MARKET, BY END USER, 2018 AND 2024 (USD MILLION) 40
FIGURE 17 GLOBAL NASH BIOMARKERS MARKET SHARE, BY REGION, 2018 (%) 45
FIGURE 18 GLOBAL NASH BIOMARKERS MARKET, BY REGION, 2018 AND 2024 (USD MILLION) 46
FIGURE 19 AMERICAS: NASH BIOMARKERS MARKET, BY REGION, 2018 AND 2024 47
FIGURE 20 NORTH AMERICA: NASH BIOMARKERS MARKET, BY COUNTRY, 2018 AND 2024 49
FIGURE 21 EUROPE: NASH BIOMARKERS MARKET, BY REGION, 2018 AND 2024 55
FIGURE 22 WESTERN EUROPE: NASH BIOMARKERS MARKET, BY COUNTRY, 2018 AND 2024 58
FIGURE 23 ASIA-PACIFIC: NASH BIOMARKERS MARKET, BY COUNTRY, 2018 AND 2024 67
FIGURE 24 MIDDLE EAST & AFRICA: NASH BIOMARKERS MARKET, BY REGION, 2018 AND 2024 76
FIGURE 25 GLOBAL NASH BIOMARKERS MARKET: COMPETITIVE LANDSCAPE 82

発刊日

2019/06

体裁

PDF / 111ページ

販売価格

4,450USD

発行

Market Research Future

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療 / バイオ・ゲノム・再生医療 / 診断・検査薬

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE